Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
The Health Care Select Sector SPDR Premium Income Fund (XLVI) belongs to the Options Strategies segment. First Trust Nasdaq Pharmaceuticals ETF (FTXH) is part of the US Health Care segment. Both ETFs have the same top 3 sector exposures: and Health Care. XLVI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.6% for FTXH. XLVI is up 0.28% year-to-date (YTD) with +$2M in YTD flows. FTXH performs better with 4.68% YTD performance, and +$7M in YTD flows. Run a side-by-side ETF comparison of XLVI and FTXH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XLVI FTXH | -1.07%-1.29% | +1.89%+6.38% | +0.28%+4.68% | n/a+24.12% | n/a+42.55% | n/a+41.63% |
| Flows | XLVI FTXH | +$788K+$5M | +$3M+$9M | +$2M+$7M | -+$10M | --$13M | -+$7M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XLVI FTXH | +10.15%+15.28% | n/a+20.56% | n/a+15.87% | n/a+15.66% |
| Max drawdown | XLVI FTXH | -3.26%-4.33% | n/a-16.42% | n/a-19.32% | n/a-19.32% |
| Max drawdown duration | XLVI FTXH | 10d10d | n/a165d | n/a393d | n/a393d |
XLVI | FTXH | |
Last sale 3/12/2026 at 1:30 PM | $25.54 | $33.78 |
| Previous close 03/11/2026 | $25.92 | $34.46 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XLVI | FTXH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XLVI | FTXH | |
|---|---|---|
| Last price | $25.54 | $33.78 |
| 1D performance | -1.47% | -1.96% |
| AuM | $13.24 M | $29.30 M |
| E/R | 0.35% | 0.6% |
XLVI | FTXH | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | SPDR | First Trust |
| Benchmark | - | NASDAQ US Smart Pharmaceuticals Index |
| N° of holdings | 57 | 49 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | July 30, 2025 | September 20, 2016 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
